The Acinetobacter calcoaceticus-Acinetobacter baumannii (Acb) complex is a major concern in veterinary medicine due to its intrinsic resistance to various antimicrobial agents, including ampicillin, amoxicillin, amoxicillin-clavulanate, and carbapenems. The increasing prevalence of multidrug-resistant (MDR) strains, particularly those producing extended-spectrum beta-lactamases (ESBLs) and carbapenemases, has been observed in animals, with a significant number of urinary tract infections being associated with these pathogens. The present study identified Acb complex strains harboring one or more resistance genes for ESBL and carbapenemase production, highlighting the growing issue of bacterial resistance in veterinary clinical practice. Phenotypic resistance profiling revealed that some Acinetobacter complex strains can hydrolyze a wide range of beta-lactams, including penicillins and third- and fourth-generation cephalosporins, while remaining resistant to cephamycins and carbapenems. Most of the ESBLs belong to Ambler’s class A, and these enzymes can be inhibited by clavulanic acid, sulbactam, tazobactam, and avibactam. The spread of these resistant strains is largely attributed to clonal expansion and horizontal gene transfer, with CTX-M, SHV, and TEM-derived ESBLs being the most clinically significant. Despite advances in molecular diagnostic methods, correlating phenotypic and genotypic data remains a significant challenge. The present findings highlight discrepancies between the phenotypic resistance patterns and the presence of resistance genes, illustrating the complexity of diagnosing and treating infections caused by Acinetobacter species. Further studies are necessary to better understand the mechanisms of resistance, improve diagnostic accuracy, and address the increasing threat of MDR bacteria in the veterinary field.